These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 15892171

  • 1. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
    Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J.
    J Pathol; 2005 Jul; 206(3):312-9. PubMed ID: 15892171
    [Abstract] [Full Text] [Related]

  • 2. Re: Torlakovic et al. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol 2005;206:312-319.
    Wang X, Ding BB, Mendez LM, Papetti M, Ye BH.
    J Pathol; 2006 Sep; 210(1):130-1; author reply 132. PubMed ID: 16841370
    [No Abstract] [Full Text] [Related]

  • 3. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
    Ree HJ, Yang WI, Kim CW, Huh J, Lee SS, Cho EY, Ko YH, Charney D.
    Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of PU.1 in follicular lymphoma.
    Torlakovic EE, Bilalovic N, Golouh R, Zidar A, Angel S.
    J Pathol; 2006 Jul; 209(3):352-9. PubMed ID: 16639693
    [Abstract] [Full Text] [Related]

  • 5. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
    Phan RT, Dalla-Favera R.
    Nature; 2004 Dec 02; 432(7017):635-9. PubMed ID: 15577913
    [Abstract] [Full Text] [Related]

  • 6. Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis.
    Jardin F, Sahota SS.
    Hematology; 2005 Apr 02; 10(2):115-29. PubMed ID: 16019457
    [Abstract] [Full Text] [Related]

  • 7. PU.1/Spi-1 is essential for the B cell-specific activity of the mouse CD72 promoter.
    Ying H, Chang JF, Parnes JR.
    J Immunol; 1998 Mar 01; 160(5):2287-96. PubMed ID: 9498769
    [Abstract] [Full Text] [Related]

  • 8. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas.
    Pittaluga S, Ayoubi TA, Wlodarska I, Stul M, Cassiman JJ, Mecucci C, Van Den Berghe H, Van De Ven WJ, De Wolf-Peeters C.
    J Pathol; 1996 Jun 01; 179(2):145-50. PubMed ID: 8758205
    [Abstract] [Full Text] [Related]

  • 9. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.
    Yegappan S, Coupland R, Arber DA, Wang N, Miocinovic R, Tubbs RR, Hsi ED.
    Mod Pathol; 2001 Nov 01; 14(11):1147-56. PubMed ID: 11706077
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM, Jürgensen GW, Johnsen HE.
    Br J Haematol; 2005 Mar 01; 128(6):813-9. PubMed ID: 15755285
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
    Loddenkemper C, Anagnostopoulos I, Hummel M, Jöhrens-Leder K, Foss HD, Jundt F, Wirth T, Dörken B, Stein H.
    J Pathol; 2004 Jan 01; 202(1):60-9. PubMed ID: 14694522
    [Abstract] [Full Text] [Related]

  • 13. The proto-oncogene BCL-6 in normal and malignant B cell development.
    Niu H.
    Hematol Oncol; 2002 Dec 01; 20(4):155-66. PubMed ID: 12469325
    [Abstract] [Full Text] [Related]

  • 14. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
    Ueda C, Akasaka T, Kurata M, Maesako Y, Nishikori M, Ichinohasama R, Imada K, Uchiyama T, Ohno H.
    Oncogene; 2002 Jan 17; 21(3):368-76. PubMed ID: 11821949
    [Abstract] [Full Text] [Related]

  • 15. Identification and characterization of a PU.1/Spi-B binding site in the bovine leukemia virus long terminal repeat.
    Dekoninck A, Calomme C, Nizet S, de Launoit Y, Burny A, Ghysdael J, Van Lint C.
    Oncogene; 2003 May 15; 22(19):2882-96. PubMed ID: 12771939
    [Abstract] [Full Text] [Related]

  • 16. [Large-cell diffuse B-cell lymphoma: heterogenous origin and prognosis from the aspect of modern diagnosis].
    Soukup J, Krsková L, Mrhalová M, Kodet R, Campr V, Kubácková K, Trnĕný M.
    Cas Lek Cesk; 2003 May 15; 142(7):417-22. PubMed ID: 14515445
    [Abstract] [Full Text] [Related]

  • 17. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
    Bai M, Agnantis NJ, Skyrlas A, Tsanou E, Kamina S, Galani V, Kanavaros P.
    Mod Pathol; 2003 May 15; 16(5):471-80. PubMed ID: 12748254
    [Abstract] [Full Text] [Related]

  • 18. Regulation of germinal center B cell differentiation. Role of the human APO-1/Fas (CD95) molecule.
    Lagresle C, Bella C, Daniel PT, Krammer PH, Defrance T.
    J Immunol; 1995 Jun 01; 154(11):5746-56. PubMed ID: 7538529
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characterization of the expression and gene promoter of CD22 in murine B cells.
    Andersson KB, Draves KE, Magaletti DM, Fujioka S, Holmes KL, Law CL, Clark EA.
    Eur J Immunol; 1996 Dec 01; 26(12):3170-8. PubMed ID: 8977319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.